We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Novel Ophthalmic Device Screens AMD Susceptibility

By HospiMedica International staff writers
Posted on 05 Jul 2017
An innovative device rapidly assesses macular pigment density, a marker for increased risk of age-related macular degeneration (AMD), the worldwide leading cause of incurable blindness in people over 55.

Developed at the University of Bristol (United Kingdom), the device is based on an entoptic phenomenon that allows certain people to perceive polarization of light as a yellow horizontal bar or bow-tie shape visible in the center of the visual field, typically occupying roughly 3–5 degrees of vision. More...
The direction of light polarization is perpendicular to the yellow bar; fainter bluish or purplish areas may be visible. Dr. Shelby Temple, PhD, of the School of Biological Sciences first encountered the phenomenon while studying the ability of octopuses, cuttlefish, and coral reef fish to see polarized light.

“What I was seeing was an effect known as Haidinger’s brushes, which is an effect that happens within the eye when people perceive polarized light. A person’s ability to see this phenomenon is linked to an aspect of eye health and can be an early indicator of disease,” explained Dr. Temple. “It became clear that the tools I had developed for fish could become the foundation for a novel ophthalmic device that could rapidly screen people for susceptibility to AMD.”

“If we can catch this early, people can make simple changes, like eating more brightly colored fruits and vegetables, quitting smoking and wearing protective eyewear, to help reduce the chances of going blind later in life,” added Dr. Temple, who is a co-founder of Azul Optics, a company created to commercialize the technology. Dr. Shelby Temple recently received the UK Biotechnology and Biological Sciences Research Council award of Innovator of the Year 2017 for his research.

“The BBSRC Innovator of the Year competition recognizes and rewards BBSRC-funded scientists that have identified and taken an active part in realizing the impact from their research,” said Karen Lewis, interim executive director at the BBSRC. “Dr. Temple’s technology has the potential to make a significant difference to people’s lives. The journey that Dr. Temple is taking to realize this opportunity from very fundamental research epitomizes the spirit of the competition. As well as being named Innovator of the Year 2017, Dr. Temple also received the award in the Commercial Impact category.”

AMD is a major cause of blindness and visual impairment in older adults in the center of the visual field (the macula) due to damage to the retina. Occurring in both dry and wet forms, AMD makes it difficult or impossible to read or recognize faces, although enough peripheral vision remains to allow other activities of daily life. In the dry (nonexudative) form, cellular debris called drusen accumulates between the retina and the choroid, and the retina can become detached. In the more severe wet (exudative) form, blood vessels grow from the choroid behind the retina, and the retina can also become detached.

Related Links:
University of Bristol


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Absorbable Monofilament Mesh
Phasix Mesh
New
Bipolar Coagulation Generator
Aesculap
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: A microneedle array worn on top of the wrist measures glucose, alcohol and lactate levels in the interstitial fluid under the skin (Photo courtesy of An-Yi Chang/UC San Diego)

Wristband Sensor Provides All-In-One Monitoring for Diabetes and Cardiovascular Care

Diabetes management is a complex and evolving challenge, particularly when it comes to accurately tracking and understanding how various factors affect blood sugar levels and overall health.... Read more

Surgical Techniques

view channel
Image: For the first time, a fluorescent-guided nerve imaging agent has shown promise for use in humans (Photo courtesy of VUMC)

Fluorescent Imaging Agent ‘Lights Up’ Nerves for Better Visualization During Surgery

Surgical nerve injury is a significant concern in head and neck surgeries, where nerves are at risk of being inadvertently damaged during procedures. Such injuries can lead to complications that may impact... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.